PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that preclinical data on XmAb942 were published in a poster to be presented during United European Gastroenterology (UEG) Week on Tuesday, October 15 in Vienna, Austria..

加利福尼亚州帕萨迪纳市（商业新闻短讯）--Xencor，Inc.（纳斯达克：XNCR），一家临床阶段的生物制药公司，开发用于治疗癌症和其他严重疾病的工程抗体，今天宣布，XmAb942的临床前数据已在海报中发布，将于10月15日星期二在奥地利维也纳举行的欧洲胃肠病学联合会（UEG）周上发布。。

XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody to be developed for patients with inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn’s disease (CD). The first generation of anti-TL1A antibodies, designed to block the interaction between the DR3 receptor and its ligand TL1A, have reduced disease activity in patients with UC and CD in multiple clinical studies.

XmAb942是一种高效，延长半衰期的研究性抗TL1A抗体，可用于炎症性肠病（如溃疡性结肠炎（UC）和克罗恩病（CD））患者。在多项临床研究中，旨在阻断DR3受体与其配体TL1A之间相互作用的第一代抗TL1A抗体降低了UC和CD患者的疾病活性。

Xencor anticipates dosing the first subject in a first-in-human study of XmAb942 in healthy volunteers during the fourth quarter of 2024 and expects to present initial data from the single-ascending dose portion of the study in the first half of 2025..

Xencor预计在2024年第四季度对健康志愿者进行XmAb942的首次人体研究中给第一个受试者服用，并预计在2025年上半年提供该研究单次递增剂量部分的初始数据。。

“We are aiming for XmAb942 to be the potential best-in-class next-generation anti-TL1A antibody, providing leading potency and less frequent dosing relative to the first generation TL1A-targeted antibodies, which have validated TL1A as an important inflammatory axis,” said John Desjarlais, Ph.D., executive vice president and chief scientific officer at Xencor.

。

“Our preclinical data suggest that in vitro potency of XmAb942 is comparable or superior to first-generation anti-TL1A antibodies. XmAb942 also demonstrates superior pharmacokinetics with a half-life of 23 days in non-human primates, which we believe supports a potential eight- to twelve-week dosing regimen in humans and could improve convenience and potentially compliance within the TL1A class.”.

“我们的临床前数据表明，XmAb942的体外效力与第一代抗TL1A抗体相当或优于第一代抗TL1A抗体。XmAb942在非人灵长类动物中也表现出优越的药代动力学，半衰期为23天，我们认为这支持了人类潜在的8至12周给药方案，可以改善TL1A类动物的便利性和潜在的依从性。”。

Xencor’s poster, titled “Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease,” will be archived under the “Publications” and the 'Events & Presentations' pages of the Company's website located at www.xencor.com..

Xencor的海报名为“发现和表征具有延长半衰期的新型高亲和力抗TL1A单克隆抗体，用于治疗炎症性肠病”，将存档在公司网站www.Xencor.com的“出版物”和“事件与演示”页面。。

About Xencor

关于Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners.

Xencor是一家临床阶段的生物制药公司，开发用于治疗癌症和其他严重疾病患者的工程抗体。使用Xencor的XmAb®技术设计的20多种候选药物正在临床开发中，多种XmAb药物由合作伙伴销售。

Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com..

Xencor的XmAb工程技术可以对蛋白质的结构进行微小的改变，从而产生新的治疗作用机制。有关更多信息，请访问www.xencor.com。。

Forward-Looking Statements

前瞻性声明

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding expectations for clinical progress, planned presentations of clinical data, new XmAb candidates, planned clinical trials, the quotations from Xencor's chief scientific officer, and other statements that are not purely statements of historical fact.

本新闻稿中的某些声明可能构成适用证券法含义内的前瞻性声明。前瞻性陈述包括不纯粹是历史事实陈述的陈述，通常可以通过使用“潜在”、“可以”、“将会”、“计划”、“可能”、“可能”、“会”、“期望”、“预期”、“寻求”、“展望”、“相信”、“承诺”、“调查”等词语来识别，也可以通过与Xencor业务相关的明示或暗示讨论来识别，包括但不限于关于临床进展预期、计划的临床数据展示、新的XmAb候选人、计划的临床试验、Xencor首席科学官的引用以及其他不纯粹是历史事实陈述的陈述。

Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results.

此类声明是根据Xencor管理层目前的信念、期望和假设做出的，并受到重大已知和未知风险、不确定性和其他因素的影响，这些风险、不确定性和其他因素可能导致实际结果、绩效或成就以及事件发生的时间与此类声明所暗示的时间有重大差异，因此这些声明不应被视为对未来绩效或结果的保证。

Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, in each case as described in Xencor's public securities filings.

此类风险包括但不限于与发现、开发、制造和商业化安全有效的人类治疗药物过程相关的风险和其他风险，包括公开披露的初步临床试验数据支持持续临床开发和特定治疗的监管批准的能力，在每种情况下，如Xencor的公共证券文件所述。

For a discussion of these and other factors, please.

有关这些因素和其他因素的讨论，请。